NCIt definition : A bispecific antibody directed against the negative immunoregulatory human cell receptor
programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial
growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic
and antineoplastic activities. Upon administration, ivonescimab simultaneously targets
and binds to both PD-1 expressed on certain T-cells and VEGF expressed on tumor cells.
The binding of ivonescimab to PD-1 prevents the activation of PD-1 by its ligands,
programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates
T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic
T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor
growth. The binding of ivonescimab to VEGF prevents binding of VEGF to its receptor
VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular
endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease
tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in
the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune
checkpoint that negatively regulates T-cell activation and effector function when
activated by its ligands PD-L1 and/or PD-L2; it plays an important role in tumor evasion
from host immunity. VEGF is overexpressed in a variety of cancers and is associated
with increased invasiveness and decreased survival.;
Semantic type(s)